A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

被引：0
|
作者：
Solomon J. Lubinga
Byamah B. Mutamba
Angelo Nganizi
Joseph B. Babigumira
机构：
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy
[2] University of Washington,Global Medicines Program, Department of Global Health
[3] Butabika National Referral Hospital for Mental,undefined
[4] Neurological and Substance Abuse Disorders,undefined
[5] Kadic Hospital,undefined
来源：
Applied Health Economics and Health Policy | 2015年 / 13卷
关键词：
Schizophrenia; Haloperidol; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：493 / 506
页数：13
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF PHARMACOGENETIC TESTING TO GUIDE TREATMENT IN SCHIZOPHRENIA
    Khani, Noushin Saadullah
    Murtough, Stephen
    Richards-Belle, Alvin
    Varney, Lauren
    Cotic, Marius
    Abidoph, Rosemary
    Barrett, Barbara
    Jin, Huajie
    Bramon, Elvira
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2024, 87 : 253 - 253
  • [32] Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
    Rosenheck, Robert A.
    Leslie, Douglas L.
    Sindelar, Jody
    Miller, Edward A.
    Lin, Haiqun
    Stroup, T. Scott
    McEvoy, Joseph
    Davis, Sonia M.
    Keefe, Richard S. E.
    Swartz, Marvin
    Perkins, Diana O.
    Hsiao, John K.
    Lieberman, Jeffrey
    AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (12): : 2080 - 2089
  • [33] VALIDATING AN INDUSTRY-SPONSORED MODEL COMPARING THE COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
    Graham, Christopher N.
    Mauskopf, Josephine
    Lawson, Anthony H.
    Ascher-Svanum, Haya
    Bruhn, David
    Watson, Peter R.
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 398 - 399
  • [34] COST-EFFECTIVENESS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA
    Omelyanovsky, V
    Avxentyeva, M.
    Ivakhnenko, O.
    Khailov, P.
    Krysanov, I
    Tsfasman, F. M.
    VALUE IN HEALTH, 2012, 15 (07) : A338 - A338
  • [35] Cost-effectiveness of current and optimal treatment for schizophrenia
    Andrews, G
    Sanderson, K
    Corry, J
    Issakidis, C
    Lapsley, H
    BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 : 427 - 435
  • [36] COST-EFFECTIVENESS STUDIES IN THE TREATMENT OF SCHIZOPHRENIA - A REVIEW
    GOLDBERG, D
    SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 1991, 26 (03) : 139 - 142
  • [37] COST-EFFECTIVENESS OF ASENAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN CANADA
    Lachaine, J.
    Beauchemin, C.
    Mathurin, K.
    Gilbert, D.
    Beillat, M.
    Corson, H.
    VALUE IN HEALTH, 2012, 15 (04) : A88 - A88
  • [38] Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States
    Svanum, Ascher H.
    Furiak, N. M.
    Klein, R. W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S3 - S4
  • [39] Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
    Furiak N.M.
    Ascher-Svanum H.
    Klein R.W.
    Smolen L.J.
    Lawson A.H.
    Conley R.R.
    Culler S.D.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [40] Cost-effectiveness of atypical antipsychotics for treatment of acute mania in the UK
    McGarry, L
    Bird, AP
    Thompson, D
    Cookson, J
    Martin, SC
    Weinstein, MC
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S261 - S261
12345